Bausch Health Companies (BHC)
Bausch Health Companies on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
8.4M
Short interest
settlement 2026-09-30
4.8
Days to cover
+1.8 days vs prior
45.0%
Short share of volume
2026-10-23
200
Fails to deliver
settlement 2026-09-30
Wed 28 Oct
Next earnings
estimated date
-$259K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in BHC is 8,404,206 shares, up 184,464 shares over the last month. Over the last 48 readings it ranged from 4,835,516 shares (31 December 2025) to 12,033,496 shares (15 October 2024). At the reported average volume of 1.7M shares a day that is 4.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bhc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 8,404,206 | -2.6% | 1,739,421 | 4.83 |
| 2026-09-15 | 8,627,598 | +5.0% | 2,817,274 | 3.06 |
| 2026-08-31 | 8,219,742 | -2.3% | 2,767,283 | 2.97 |
| 2026-08-14 | 8,415,649 | +11.3% | 4,962,454 | 1.70 |
| 2026-07-31 | 7,563,382 | +2.6% | 5,064,885 | 1.49 |
| 2026-07-15 | 7,370,473 | +0.5% | 1,977,680 | 3.73 |
| 2026-06-30 | 7,332,632 | -1.5% | 3,907,788 | 1.88 |
| 2026-06-15 | 7,441,129 | +21.5% | 2,209,833 | 3.37 |
| 2026-05-29 | 6,124,091 | +2.7% | 1,604,043 | 3.82 |
| 2026-05-15 | 5,965,122 | -6.3% | 1,749,810 | 3.41 |
| 2026-04-30 | 6,366,152 | +1.4% | 1,893,429 | 3.36 |
| 2026-04-15 | 6,276,506 | +4.8% | 1,110,861 | 5.65 |
| 2026-03-31 | 5,986,444 | -4.9% | 1,508,907 | 3.97 |
| 2026-03-13 | 6,296,804 | +13.7% | 3,150,332 | 2.00 |
| 2026-02-27 | 5,539,129 | -1.1% | 2,273,204 | 2.44 |
| 2026-02-13 | 5,598,262 | +3.4% | 1,829,300 | 3.06 |
| 2026-01-30 | 5,413,725 | +7.7% | 2,710,264 | 2.00 |
| 2026-01-15 | 5,027,211 | +4.0% | 1,884,521 | 2.67 |
| 2025-12-31 | 4,835,516 | -24.6% | 2,176,462 | 2.22 |
| 2025-12-15 | 6,413,854 | +13.5% | 3,153,751 | 2.03 |
| 2025-11-28 | 5,649,348 | -14.4% | 2,389,234 | 2.36 |
| 2025-11-14 | 6,659,022 | +2.8% | 3,084,123 | 2.16 |
| 2025-10-31 | 6,478,871 | -13.2% | 2,520,965 | 2.57 |
| 2025-10-15 | 7,464,358 | -3.1% | 1,306,408 | 5.71 |
| 2025-09-30 | 7,705,899 | -2.8% | 1,890,705 | 4.08 |
| 2025-09-15 | 7,927,363 | -4.0% | 2,044,361 | 3.88 |
| 2025-08-29 | 8,256,861 | -0.5% | 2,257,302 | 3.66 |
| 2025-08-15 | 8,300,517 | +13.9% | 6,361,804 | 1.30 |
| 2025-07-31 | 7,286,725 | -2.0% | 1,454,849 | 5.01 |
| 2025-07-15 | 7,436,683 | -10.7% | 1,683,939 | 4.42 |
| 2025-06-30 | 8,323,683 | -4.1% | 2,896,304 | 2.87 |
| 2025-06-13 | 8,675,986 | +0.8% | 3,048,082 | 2.85 |
| 2025-05-30 | 8,606,924 | +5.3% | 1,001,975 | 8.59 |
| 2025-05-15 | 8,174,634 | -17.1% | 2,151,638 | 3.80 |
| 2025-04-30 | 9,864,778 | +9.4% | 2,869,974 | 3.44 |
| 2025-04-15 | 9,020,233 | +14.9% | 3,176,307 | 2.84 |
| 2025-03-31 | 7,852,454 | +29.6% | 1,786,604 | 4.40 |
| 2025-03-14 | 6,061,522 | -6.0% | 1,229,686 | 4.93 |
| 2025-02-28 | 6,449,195 | -17.0% | 3,260,802 | 1.98 |
| 2025-02-14 | 7,773,356 | +12.6% | 3,044,378 | 2.55 |
| 2025-01-31 | 6,905,591 | -16.3% | 4,728,940 | 1.46 |
| 2025-01-15 | 8,252,863 | +17.3% | 1,540,734 | 5.36 |
| 2024-12-31 | 7,034,594 | -12.1% | 1,142,313 | 6.16 |
| 2024-12-13 | 8,001,992 | -22.0% | 1,550,279 | 5.16 |
| 2024-11-29 | 10,264,219 | +9.9% | 1,316,662 | 7.80 |
| 2024-11-15 | 9,343,194 | -19.8% | 2,091,666 | 4.47 |
| 2024-10-31 | 11,651,014 | -3.2% | 1,903,361 | 6.12 |
| 2024-10-15 | 12,033,496 | -18.6% | 1,390,241 | 8.66 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of BHC volume is 45.0%, down 3.0 points over the last five sessions. Over the last 30 readings it ranged from 24.3% (22 September 2026) to 63.1% (21 October 2026). The latest reading is in line with the 30-session average of 44.7%, on 953K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 429K | 953K | 45.0% | 980 |
| 2026-10-22 | 212K | 408K | 52.1% | 110 |
| 2026-10-21 | 440K | 697K | 63.1% | 0 |
| 2026-10-20 | 299K | 767K | 39.0% | 0 |
| 2026-10-19 | 182K | 556K | 32.7% | 0 |
| 2026-10-16 | 377K | 785K | 48.0% | 0 |
| 2026-10-15 | 348K | 797K | 43.7% | 5 |
| 2026-10-14 | 242K | 591K | 40.9% | 0 |
| 2026-10-13 | 236K | 513K | 46.1% | 8 |
| 2026-10-12 | 579K | 1.1M | 54.4% | 3,800 |
| 2026-10-09 | 166K | 418K | 39.7% | 0 |
| 2026-10-08 | 187K | 389K | 48.1% | 0 |
| 2026-10-07 | 459K | 732K | 62.7% | 20 |
| 2026-10-06 | 608K | 977K | 62.2% | 4,632 |
| 2026-10-05 | 294K | 566K | 51.9% | 0 |
| 2026-10-02 | 629K | 998K | 63.0% | 6,258 |
| 2026-10-01 | 197K | 455K | 43.3% | 0 |
| 2026-09-30 | 257K | 514K | 49.9% | 0 |
| 2026-09-29 | 235K | 494K | 47.6% | 100 |
| 2026-09-28 | 240K | 575K | 41.7% | 4 |
| 2026-09-25 | 136K | 446K | 30.5% | 432 |
| 2026-09-24 | 356K | 900K | 39.6% | 0 |
| 2026-09-23 | 164K | 484K | 33.9% | 12 |
| 2026-09-22 | 166K | 683K | 24.3% | 11 |
| 2026-09-21 | 253K | 621K | 40.8% | 3,000 |
| 2026-09-18 | 284K | 717K | 39.6% | 1,614 |
| 2026-09-17 | 281K | 735K | 38.2% | 543 |
| 2026-09-16 | 302K | 701K | 43.1% | 0 |
| 2026-09-15 | 322K | 688K | 46.7% | 1,048 |
| 2026-09-14 | 246K | 831K | 29.6% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in BHC is 200 shares, down 340 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (9 July 2026) to 450,836 shares (1 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 200 | $5.80 | $1K |
| 2026-09-17 | 540 | $5.69 | $3K |
| 2026-09-14 | 3,770 | $5.86 | $22K |
| 2026-09-10 | 108 | $6.16 | $665 |
| 2026-09-09 | 7,678 | $6.43 | $49K |
| 2026-09-04 | 2,267 | $6.76 | $15K |
| 2026-09-01 | 450,836 | $6.37 | $2.9M |
| 2026-08-31 | 107,686 | $6.32 | $681K |
| 2026-08-27 | 48 | $6.51 | $312 |
| 2026-08-24 | 15,263 | $6.44 | $98K |
| 2026-08-20 | 153,549 | $6.89 | $1.1M |
| 2026-08-19 | 650 | $6.93 | $5K |
| 2026-08-18 | 650 | $6.58 | $4K |
| 2026-08-17 | 650 | $6.51 | $4K |
| 2026-08-14 | 1,997 | $6.34 | $13K |
| 2026-08-13 | 1,000 | $6.21 | $6K |
| 2026-08-07 | 32,776 | $5.91 | $194K |
| 2026-08-06 | 6,900 | $6.29 | $43K |
| 2026-08-05 | 15,788 | $6.44 | $102K |
| 2026-08-04 | 14,536 | $7.00 | $102K |
| 2026-08-03 | 359,321 | $6.89 | $2.5M |
| 2026-07-30 | 1,500 | $4.68 | $7K |
| 2026-07-22 | 188,595 | $4.52 | $852K |
| 2026-07-21 | 98,323 | $4.68 | $460K |
| 2026-07-20 | 202 | $4.83 | $976 |
| 2026-07-17 | 11,532 | $4.93 | $57K |
| 2026-07-16 | 21,638 | $4.89 | $106K |
| 2026-07-09 | 1 | $4.91 | $5 |
| 2026-07-08 | 81,562 | $4.91 | $400K |
| 2026-07-07 | 36,756 | $4.81 | $177K |
Insider trades
SEC Form 4, newest first. JSONInsiders at BHC reported 1 open-market sell worth $259K in the last 90 days and no open-market buys. Latest filing: Paulson John (Director) on 2026-09-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Paulson John | Director | Grant | 11K | $5.83 | $62K | 441K |
| 2026-09-30 | WECHSLER AMY B | Director | Grant | 1K | $5.83 | $7K | 316K |
| 2026-09-30 | LEUNG SANDRA | Director | Grant | 6K | $5.83 | $34K | 103K |
| 2026-08-19 | Lenar Aimee J. | President, US Pharma | Sell | 37K | $7.03 | $259K | 335K |
| 2026-07-17 | Lenar Aimee J. | President, US Pharma | Tax withholding | 5K | $4.83 | $25K | 372K |
| 2026-07-15 | Lenar Aimee J. | President, US Pharma | Tax withholding | 23K | $4.89 | $114K | 377K |
| 2026-07-14 | LEE STEVEN HYOSIG | SVP, Controller & CAO | Tax withholding | 3K | $4.75 | $15K | 70K |
| 2026-06-30 | WECHSLER AMY B | Director | Grant | 1K | $4.93 | $7K | 315K |
| 2026-06-30 | Paulson John | Director | Grant | 13K | $4.93 | $62K | 430K |
| 2026-06-30 | LEUNG SANDRA | Director | Grant | 7K | $4.93 | $34K | 97K |
| 2026-05-22 | WECHSLER AMY B | Director | Grant | 46K | $0.00 | $0 | 314K |
| 2026-05-22 | ROBERTS EIRY | Director | Grant | 46K | $0.00 | $0 | 46K |
| 2026-05-22 | POWER ROBERT N | Director | Grant | 46K | $0.00 | $0 | 301K |
| 2026-05-22 | Paulson John | Director | Grant | 46K | $0.00 | $0 | 418K |
| 2026-05-22 | LEUNG SANDRA | Director | Grant | 46K | $0.00 | $0 | 90K |
| 2026-05-22 | Lee Frank D. | Director | Grant | 46K | $0.00 | $0 | 95K |
| 2026-05-22 | KAVANAGH SARAH B | Director | Grant | 46K | $0.00 | $0 | 282K |
| 2026-05-22 | GOETTLER MICHAEL | Director | Grant | 46K | $0.00 | $0 | 76K |
| 2026-05-22 | Garcia Christian A | Director | Grant | 46K | $0.00 | $0 | 136K |
| 2026-05-19 | Lee Frank D. | Director | Sell | 24K | $5.43 | $133K | 49K |
| 2026-03-31 | LEUNG SANDRA | Director | Grant | 6K | $5.40 | $32K | 44K |
| 2026-03-31 | Paulson John | Director | Grant | 12K | $5.40 | $62K | 372K |
| 2026-03-31 | WECHSLER AMY B | Director | Grant | 1K | $5.40 | $7K | 268K |
| 2026-03-03 | Carson Seana | EVP, General Counsel | Sell | 4K | $5.77 | $26K | 617K |
| 2026-03-02 | Carson Seana | EVP, General Counsel | Other transaction | 138K | $5.95 | $821K | 621K |
| 2026-03-02 | Carson Seana | EVP, General Counsel | Tax withholding | 17K | $5.95 | $101K | 759K |
| 2026-03-02 | Carson Seana | EVP, General Counsel | Sell | 7K | $5.78 | $40K | 776K |
| 2026-03-02 | APPIO THOMAS | Chief Executive Officer | Other transaction | 1.1M | $5.95 | $6.8M | 2.3M |
| 2026-03-02 | APPIO THOMAS | Chief Executive Officer | Tax withholding | 84K | $5.95 | $498K | 3.5M |
| 2026-02-27 | Carson Seana | EVP, General Counsel | Sell | 8K | $5.95 | $50K | 809K |
| 2026-02-27 | Charhon Jean-Jacques | EVP, CFO | Tax withholding | 49K | $5.93 | $291K | 706K |
| 2026-02-27 | Carson Seana | EVP, General Counsel | Tax withholding | 26K | $5.93 | $156K | 783K |
| 2026-02-27 | APPIO THOMAS | Chief Executive Officer | Tax withholding | 83K | $5.93 | $493K | 3.5M |
| 2026-02-26 | Lenar Aimee J. | EVP, US Pharma | Tax withholding | 18K | $6.04 | $106K | 400K |
| 2026-02-26 | Carson Seana | EVP, General Counsel | Tax withholding | 32K | $6.04 | $195K | 818K |
| 2026-02-26 | Charhon Jean-Jacques | EVP, CFO | Tax withholding | 36K | $6.04 | $217K | 756K |
| 2026-02-26 | APPIO THOMAS | Chief Executive Officer | Tax withholding | 117K | $6.04 | $704K | 3.6M |
| 2026-02-25 | LEE STEVEN HYOSIG | SVP, Controller & CAO | Grant | 46K | $0.00 | $0 | 73K |
| 2026-02-25 | Lenar Aimee J. | EVP, US Pharma | Grant | 157K | $0.00 | $0 | 418K |
| 2026-02-25 | Carson Seana | EVP, General Counsel | Grant | 212K | $0.00 | $0 | 850K |
| 2026-02-25 | Charhon Jean-Jacques | EVP, CFO | Grant | 276K | $0.00 | $0 | 792K |
| 2026-02-25 | APPIO THOMAS | Chief Executive Officer | Grant | 815K | $0.00 | $0 | 3.7M |
| 2026-02-09 | Carson Seana | EVP, General Counsel | Grant | 138K | $0.00 | $0 | 638K |
| 2026-02-09 | APPIO THOMAS | Chief Executive Officer | Grant | 1.1M | $0.00 | $0 | 2.9M |
| 2025-12-31 | Paulson John | Director | Grant | 9K | $0.00 | $0 | 360K |
| 2025-12-31 | LEUNG SANDRA | Director | Grant | 5K | $0.00 | $0 | 38K |
| 2025-12-31 | WECHSLER AMY B | Director | Grant | 989 | $0.00 | $0 | 266K |
| 2025-11-25 | PAULSON & CO. INC. | TenPercentOwner | Buy | 2.5M | $6.25 | $15.6M | 73.3M |
| 2025-09-30 | Paulson John | Director | Grant | 10K | $0.00 | $0 | 351K |
| 2025-09-30 | LEUNG SANDRA | Director | Grant | 4K | $0.00 | $0 | 34K |
| 2025-09-30 | WECHSLER AMY B | Director | Grant | 1K | $0.00 | $0 | 265K |
| 2025-09-08 | Carson Seana | EVP, General Counsel | Sell | 13K | $7.31 | $98K | 500K |
| 2025-09-05 | Carson Seana | EVP, General Counsel | Tax withholding | 51K | $7.35 | $377K | 513K |
| 2025-08-21 | Lee Frank D. | Director | Sell | 16K | $7.66 | $122K | 74K |
| 2025-08-14 | Paulson John | Director | Buy | 34.7M | $9.00 | $312.5M | 70.8M |
| 2025-08-13 | Paulson John | Director | Buy | 86K | $7.06 | $610K | 36.0M |
| 2025-08-12 | Paulson John | Director | Buy | 1.2M | $6.88 | $8.0M | 35.9M |
| 2025-08-11 | Paulson John | Director | Buy | 2.0M | $6.35 | $12.7M | 34.8M |
| 2025-07-25 | GOETTLER MICHAEL | Director | Grant | 30K | $0.00 | $0 | 30K |
| 2025-07-25 | LEUNG SANDRA | Director | Grant | 30K | $0.00 | $0 | 30K |
| 2025-07-17 | Lenar Aimee J. | EVP, US Pharma | Grant | 31K | $0.00 | $0 | 261K |
| 2025-07-15 | Lenar Aimee J. | EVP, US Pharma | Tax withholding | 23K | $6.42 | $146K | 230K |
| 2025-07-14 | LEE STEVEN HYOSIG | SVP, Controller & CAO | Grant | 27K | $0.00 | $0 | 27K |
| 2025-06-30 | Paulson John | Director | Grant | 9K | $0.00 | $0 | 341K |
| 2025-06-30 | ICAHN BRETT | Director | Grant | 4K | $0.00 | $0 | 220K |
| 2025-06-30 | WECHSLER AMY B | Director | Grant | 1K | $0.00 | $0 | 264K |
| 2025-06-13 | Paulson John | Director | Buy | 3.6M | $5.94 | $21.2M | 32.8M |
| 2025-06-12 | Paulson John | Director | Buy | 1.0M | $5.47 | $5.5M | 29.2M |
| 2025-06-11 | Paulson John | Director | Buy | 1.0M | $5.24 | $5.4M | 28.2M |
| 2025-06-10 | Paulson John | Director | Buy | 754K | $5.05 | $3.8M | 27.2M |
| 2025-05-16 | WECHSLER AMY B | Director | Grant | 54K | $0.00 | $0 | 263K |
| 2025-05-16 | POWER ROBERT N | Director | Grant | 54K | $0.00 | $0 | 255K |
| 2025-05-16 | Paulson John | Director | Grant | 54K | $0.00 | $0 | 332K |
| 2025-05-16 | Mulligan Richard | Director | Grant | 54K | $0.00 | $0 | 156K |
| 2025-05-16 | Miller Steven D | Director | Grant | 54K | $0.00 | $0 | 229K |
| 2025-05-16 | Lee Frank D. | Director | Grant | 54K | $0.00 | $0 | 90K |
| 2025-05-16 | KAVANAGH SARAH B | Director | Grant | 54K | $0.00 | $0 | 236K |
| 2025-05-16 | ICAHN BRETT | Director | Grant | 54K | $0.00 | $0 | 216K |
| 2025-05-16 | Garcia Christian A | Director | Grant | 54K | $0.00 | $0 | 90K |
| 2025-03-31 | Paulson John | Director | Grant | 10K | $6.47 | $62K | 278K |
| 2025-03-31 | ICAHN BRETT | Director | Grant | 5K | $6.47 | $33K | 162K |
| 2025-03-31 | WECHSLER AMY B | Director | Grant | 1K | $6.47 | $7K | 209K |
| 2025-02-28 | Carson Seana | EVP, General Counsel | Tax withholding | 26K | $7.44 | $196K | 564K |
| 2025-02-28 | Carson Seana | EVP, General Counsel | Tax withholding | 6K | $7.44 | $45K | 608K |
| 2025-02-28 | Carson Seana | EVP, General Counsel | Tax withholding | 17K | $7.44 | $126K | 591K |
| 2025-02-28 | APPIO THOMAS | Chief Executive Officer | Tax withholding | 97K | $7.44 | $721K | 1.8M |
| 2025-02-28 | APPIO THOMAS | Chief Executive Officer | Tax withholding | 25K | $7.44 | $185K | 2.0M |
| 2025-02-28 | APPIO THOMAS | Chief Executive Officer | Tax withholding | 85K | $7.44 | $633K | 1.9M |
| 2025-02-28 | Barresi John S | SVP, Controller & CAO | Tax withholding | 3K | $7.44 | $21K | 197K |
| 2025-02-28 | Barresi John S | SVP, Controller & CAO | Tax withholding | 5K | $7.44 | $38K | 192K |
| 2025-02-26 | APPIO THOMAS | Chief Executive Officer | Grant | 635K | $0.00 | $0 | 2.0M |
| 2025-02-26 | Charhon Jean-Jacques | EVP, CFO | Grant | 217K | $0.00 | $0 | 515K |
| 2025-02-26 | Carson Seana | EVP, General Counsel | Grant | 181K | $0.00 | $0 | 614K |
| 2025-02-26 | Lenar Aimee J. | EVP, US Pharma | Grant | 108K | $0.00 | $0 | 253K |
| 2025-02-26 | Barresi John S | SVP, Controller & CAO | Grant | 50K | $0.00 | $0 | 200K |
| 2024-12-31 | ICAHN BRETT | Director | Grant | 4K | $8.06 | $33K | 157K |
| 2024-12-31 | Paulson John | Director | Grant | 8K | $8.06 | $62K | 268K |
| 2024-12-31 | WECHSLER AMY B | Director | Grant | 852 | $8.06 | $7K | 208K |
| 2024-12-02 | Carson Seana | EVP, General Counsel | Sell | 440 | $8.35 | $4K | 433K |
| 2024-11-29 | Carson Seana | EVP, General Counsel | Tax withholding | 2K | $8.37 | $14K | 434K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for BHC worth $507K at the prices reported; 1 in the last 90 days worth $259K. Latest: Lenar Aimee J. filed on 2026-08-19 to sell 36,827 shares ($259K) from 2026-08-19.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-19 | Lenar Aimee J.Officer | 37K | $259K | 0.010% | 2026-08-19 | Fidelity Brokerage Services LLC |
| 2026-05-19 | Lee Frank D.Director | 24K | $133K | 0.007% | 2026-05-19 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Carson SeanaOfficer | 4K | $26K | 0.001% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Carson SeanaOfficer | 7K | $40K | 0.002% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-27 | Carson SeanaOfficer | 8K | $50K | 0.002% | 2026-02-27 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSONNo holder on file reports 5% or more of BHC in its latest filing.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2025-11-14 | 13G/Ano. 1 | NOMURA HOLDINGS INCparent holding company | 15.7M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | NOMURA GLOBAL FINANCIAL PRODUCTS INCbroker-dealer | 15.7M | 4.2% | 2025-09-30 |
13F holders
Tracked managers holding BHC at their latest 13F. JSON9 of the 30 tracked managers held BHC at their latest 13F, $418.0M in total at quarter-end prices. Paulson & Co. is the largest at $361.2M (14.0% of its portfolio) as of 2026-06-30. Over the prior quarter 7 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Paulson & Co. | 2026-06-30 | 73.3M | $361.2M | 14.02% | 0 |
| D. E. Shaw & Co. | 2026-06-30 | 2.7M | $13.3M | 0.01% | +2.1M |
| Point72 Asset Management | 2026-06-30 | 2.2M | $11.0M | 0.01% | +886K |
| Two Sigma Investments | 2026-06-30 | 2.1M | $10.5M | 0.01% | +557K |
| Renaissance Technologies | 2026-06-30 | 1.3M | $6.5M | 0.01% | -251K |
| Citadel Advisors | 2026-06-30 | 1.1M | $5.4M | 0.00% | +193K |
| Millennium Management | 2026-06-30 | 1.1M | $5.4M | 0.00% | +658K |
| Bridgewater Associates | 2026-06-30 | 866K | $4.3M | 0.02% | +196K |
| AQR Capital Management | 2026-06-30 | 82K | $406K | 0.00% | +20K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Bausch Health Companies reported revenue of $2.85B, up 12.7% from the same quarter a year earlier, and net income of $258.0M (0.68 diluted EPS). In FY 2025 it generated $1.40B of operating cash flow. As of 2026-06-30, cash was $1.82B against $20.74B of debt.
- Cash
- $1.82B
- Debt
- $20.74B
- Equity
- -$1.77B
- Total assets
- $24.79B
- Shares outstanding
- 373,990,561
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $2.85B | $258.0M | 9.0% | 0.68 |
| Q1 FY 2026 | 2026-03-31 | $2.52B | -$1.42B | -56.4% | -3.82 |
| Q4 FY 2025derived | 2025-12-31 | $2.80B | -$112.0M | -4.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $2.68B | $179.0M | 6.7% | 0.48 |
| Q2 FY 2025 | 2025-06-30 | $2.53B | $148.0M | 5.8% | 0.40 |
| Q1 FY 2025 | 2025-03-31 | $2.26B | -$58.0M | -2.6% | -0.16 |
| Q4 FY 2024derived | 2024-12-31 | $2.56B | $93.0M | 3.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $2.51B | -$85.0M | -3.4% | -0.23 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $10.27B | $157.0M | $1.40B | $397.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $9.63B | -$46.0M | $1.60B | $337.0M | n/a | n/a |
| FY 2023 | 2023-12-31 | $8.76B | -$592.0M | $1.03B | $215.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $8.12B | -$225.0M | -$728.0M | $218.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $8.43B | -$948.0M | $1.43B | $269.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-24 from the cover page.
What this page is
Bausch Health Companies in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Bausch Health Companies (BHC), SEC CIK 885590, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-19.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2025-11-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 885590Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of BHC is sold short?
What is BHC's daily short volume?
Does BHC have fails to deliver?
Are BHC insiders buying or selling?
Have BHC insiders filed to sell?
Who owns 5% or more of BHC?
What did BHC report last quarter?
Which tracked 13F managers own BHC?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.